

## Rytary - (23.75/95mg, 36.25/145mg, 48.75/195mg; Capsule, extended release)

|                              |   |                             |                     |
|------------------------------|---|-----------------------------|---------------------|
| <b>Generic Name</b>          | Carbidopa and Levodopa  | <b>Innovator</b>            | Impax               |
| <b>Dosage</b>                | 23.75/95mg, 36.25/145mg, 48.75/195mg; Capsule, extended release | <b>Branded US Sales</b>     | Less Than \$1000 mn |
| <b>Probable FTF</b>          | Less Than 5   | <b>Known Para IV Filers</b> | More Than 5         |
| <b>Other ANDA developers</b> | More Than 5   | <b>Tentative Approvals</b>  | Less Than 5         |
| <b>Final Approvals</b>       | None  | <b>Generic Launches</b>     | None                |
| <b>Indication</b>            | Indicated for Parikinson's disease.                             |                             |                     |
| <b>Complexities</b>          | Yes   |                             |                     |

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

## Rytary - (61.25mg/ 245mg Capsule, extended release)

|                              |  |                             |                     |
|------------------------------|--|-----------------------------|---------------------|
| <b>Generic Name</b>          | Carbidopa and Levodopa                   | <b>Innovator</b>            | Impax               |
| <b>Dosage</b>                | 61.25mg/ 245mg Capsule, extended release | <b>Branded US Sales</b>     | Less Than \$1000 mn |
| <b>Probable FTF</b>          | Less Than 5                              | <b>Known Para IV Filers</b> | More Than 5         |
| <b>Other ANDA developers</b> | More Than 5                              | <b>Tentative Approvals</b>  | Less Than 5         |
| <b>Final Approvals</b>       | None                                     | <b>Generic Launches</b>     | None                |
| <b>Indication</b>            | Indicated for Parkinsons disease         |                             |                     |
| <b>Complexities</b>          | Yes                                      |                             |                     |

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.